Axovant Sciences Ltd. | Mutual Funds
Mutual Funds that own Axovant Sciences Ltd.
iShares Nasdaq Biotechnology ETF
1,242,796
1.02%
-16,254
0.03%
09/06/2018
PRIMECAP Odyssey Aggressive Growth Fund
825,000
0.68%
-1,383,000
0.02%
06/30/2018
UBS (Lux) Equity Fund - Biotech
283,360
0.23%
0
0.06%
01/31/2018
Vanguard Investment Series Plc - US Opportunities Fund
193,900
0.16%
-101,400
0.02%
06/30/2018
BioShares Biotechnology Clinical Trials Fund
133,957
0.11%
0
0.64%
09/05/2018
Vanguard Health Care Index Fund
70,132
0.06%
612
0%
07/31/2018
Fidelity Spartan Small Cap Index Fund
65,726
0.05%
1,706
0%
04/30/2018
EQ/Small Company Index Portfolio
60,000
0.05%
0
0.01%
03/31/2018
CREF Stock Account
59,855
0.05%
-101,840
0%
03/31/2018
AXA 2000 Managed Volatility Portfolio
50,079
0.04%
0
0%
03/31/2018
| Address |
11-12 St. James's Square
London London & South East SWIY 4LB
United Kingdom
|
|
Employees
|
- |
| Website |
http://www.axovant.com |
| Updated |
09/14/2018 |
| Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics in the fields of neurology and psychiatry. Its therapeutic focus are Parkinson's Disease and Lewy Body Dementia. It operates through the following geographical sgements: United States, Switzerland, Bermuda, and Other. |
